कंपनी का अवलोकन
Generate Biomedicines, Inc., a prominent entity within the healthcare sector, specializes in the biotechnology industry by leveraging generative biology and machine learning for drug discovery and development. The company focuses on programming novel protein therapeutics in the United States and utilizes protein-based modalities to advance its drug development pipeline, with a specific product including GB-0895. As of the latest data, the company possesses a market capitalization of $1.47 billion and employs a workforce of 312 individuals to support its extensive research and operational activities. The annual revenue recorded over the trailing twelve months stands at $31.89 million, which, when combined with the market cap, suggests a high price-to-sales multiple often characteristic of early-stage biotechnology firms where future potential is valued significantly higher than current operational output.
वित्तीय स्वास्थ्य
The financial statements for Generate Biomedicines, Inc. reveal a trailing twelve-month revenue of $31.89 million contrasted against a net income loss of $249,523,008 and an EBITDA loss of $221,887,008, indicating a substantial gap between top-line generation and bottom-line profitability. This significant disparity highlights a cost structure dominated by heavy research and development expenditures or operational inefficiencies that currently outweigh all revenue streams generated. The company reports a free cash flow of $-119,101,624, which signifies a continuous cash burn that limits immediate financial flexibility and necessitates external capital funding to sustain operations. Regarding profitability metrics, the gross margin is recorded at 0.0%, suggesting that cost of goods sold currently equals total revenue, while the operating margin stands at -737.0% and the profit margin at 0.0%, both figures pointing to severe operational losses relative to sales. Although specific cash and debt figures are not disclosed in the available data, the debt-to-equity ratio is listed as N/A, preventing a direct assessment of leverage, yet the negative return metrics suggest a balance sheet under financial pressure. The current ratio is 2.85, which indicates that the company holds sufficient current assets to cover its short-term liabilities more than twice over, providing a degree of liquidity stability despite operational losses. Furthermore, the return on equity is -81.7% and the return on assets is -34.6%, revealing that management's effectiveness in generating shareholder value and utilizing asset bases is currently negative due to the prevailing financial losses.
मूल्यांकन आकलन
The valuation metrics for Generate Biomedicines, Inc. show a P/E ratio (TTM) of N/A due to losses, while the forward P/E is -5.44, a negative figure that implies the market is pricing in significant future earnings expectations or is utilizing non-standard valuation models for loss-making biotech entities. The price-to-book ratio is -0.94, indicating that the market capitalization is less than the book value of equity, a scenario often seen in distressed or pre-revenue biotechnology companies where asset values may not reflect intangible R&D potential. The price-to-sales ratio is 46.08, a very high multiple that suggests investors are willing to pay a substantial premium for every dollar of revenue, betting heavily on the success of its protein therapeutics pipeline. Additionally, the EV/EBITDA ratio is N/A, which prevents traditional enterprise value comparisons but underscores the difficulty in valuing companies with negative earnings using standard cash-flow-based multiples. The stock has traded within a 52-week range between $11.00 and $15.32, meaning the current price sits somewhere within this historical volatility band, reflecting the speculative nature of investing in a company with no current profitability. The beta value is N/A, so a direct comparison to broader market volatility cannot be made using this specific metric, though the high price-to-sales ratio implies the stock price is highly sensitive to clinical trial results and regulatory approvals rather than general market movements.
Growth & Income
The available data lists revenue growth year-over-year and earnings growth year-over-year as N/A, precluding an analysis of growth rates between periods or a comparison of earnings acceleration against revenue expansion. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company does not distribute cash to shareholders and instead retains all earnings to fund its high-burn research and development initiatives. This reinvestment strategy is typical for biotechnology firms in the discovery phase, where capital is directed toward programming novel protein therapeutics rather than paying dividends to investors. Consequently, the overall growth and income profile is defined by zero current income distribution and an undefined historical growth rate based on the provided facts, relying entirely on future potential rather than past performance or current cash returns.